Chris Kresser: I haven’t found that to be an important clinical distinction. We talked a bit in the HPA axis unit about the differences between what you would do in a hypercortisolism state and a hypocortisolism state, and there aren’t a lot of good ways for testing outside of a research setting for SAS activation above and beyond the DUTCH testing that we’re already using and some of the other tests we talked about. Really, especially from a behavioral and lifestyle perspective, the changes that you’re going to suggest are largely the same, so I don’t think it makes a clinically meaningful difference.